Nexus between mitochondrial function, iron, copper and glutathione in Parkinson's disease
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Parkinson's disease is neuropathologically characterised by loss of catecholamine neurons in vulnerable brain regions including substantia nigra pars compacta and locus coeruleus. This review discusses how the susceptibility of these regions is defined by their shared biochemical characteristics that differentiate them from other neurons. Parkinson's disease is biochemically characterised by mitochondrial dysfunction, accumulation of iron, diminished copper content and depleted glutathione levels in these regions. This review also discusses this neuropathology, and provides evidence for how these pathological features are mechanistically linked to each other. This leads to the conclusion that disruption of mitochondrial function, or iron, copper or glutathione metabolism in isolation provokes the pathological impairment of them all. This creates a vicious cycle that drives pathology leading to mitochondrial failure and neuronal cell death in vulnerable brain regions. HIGHLIGHTSDistinct characteristics demarcate vulnerable brain regions in Parkinson's disease.PD involves disruption of mitochondrial function, iron, copper and glutathione levels.Perturbation of any one of these provokes the pathological impairment of the others.Hence these core pathological changes in PD are mechanistically linked.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition
Doll, S., Proneth, B., Tyurina, Y. Y., Panzilius, E., Kobayashi, S., Ingold, I., Irmler, M., Beckers, J., Aichler, M., Walch, A., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2239 · Cited by 4,293 · cited 2×
“, 2017) and its inhibition is sufficient to block ferroptosis (Doll et al., 2017; Kagan et al., 2017).”
Autophagy promotes ferroptosis by degradation of ferritin
Hou, W., Xie, Y., Song, X., Sun, X., Lotze, M. T., Zeh, H. J., Kang, R., & Tang, D. (2016) · Autophagy · doi:10.1080/15548627.2016.1187366 · Cited by 2,332
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283 · cited 1×
“There is abundant evidence for impaired activity of mitochondrial complex I in PD post-mortem tissue, profoundly from SN, but also other brain regions including frontal cortex and the periphery (Bindoff et al., 1989; Mann et al., 1994; Mizuno et al., 1989; Parker et al., 1989, 2008; Schapira et al., 1990; Schapira et…”
Brigelius-Flohé, R., & Maiorino, M. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.11.020 · Cited by 1,904
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383
Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149
DEXTER, D. T., CARAYON, A., JAVOY-AGID, F., AGID, Y., WELLS, F. R., DANIEL, S. E., LEES, A. J., JENNER, P., & MARSDEN, C. D. (1991) · Brain · doi:10.1093/brain/114.4.1953 · Cited by 1,043
Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxia
Rötig, A., de Lonlay, P., Chretien, D., Foury, F., Koenig, M., Sidi, D., Munnich, A., & Rustin, P. (1997) · Nature Genetics · doi:10.1038/ng1097-215 · Cited by 991
Hambright, W. S., Fonseca, R. S., Chen, L., Na, R., & Ran, Q. (2017) · Redox Biology · doi:10.1016/j.redox.2017.01.021 · Cited by 851
Expression of Nrf2 in Neurodegenerative Diseases
Ramsey, C. P., Glass, C. A., Montgomery, M. B., Lindl, K. A., Ritson, G. P., Chia, L. A., Hamilton, R. L., Chu, C. T., & Jordan-Sciutto, K. L. (2007) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e31802d6da9 · Cited by 760
Do Van, B., Gouel, F., Jonneaux, A., Timmerman, K., Gelé, P., Pétrault, M., Bastide, M., Laloux, C., Moreau, C., Bordet, R., et al. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.05.011 · Cited by 689
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
Zucca, F. A., Segura-Aguilar, J., Ferrari, E., Muñoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., & Zecca, L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.012 · Cited by 659
Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620
Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export
Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., Wong, B. X. W., Adlard, P. A., Cherny, R. A., Lam, L. Q., et al. (2012) · Nature Medicine · doi:10.1038/nm.2613 · Cited by 594 · cited 4×
“knockout mice, which exhibit iron accumulation and parkinsonism (Lei et al., 2012).”
InfluentialChen, P.-C., Vargas, M. R., Pani, A. K., Smeyne, R. J., Johnson, D. A., Kan, Y. W., & Johnson, J. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813361106 · Cited by 579
Rogers, J. T., Randall, J. D., Cahill, C. M., Eder, P. S., Huang, X., Gunshin, H., Leiter, L., McPhee, J., Sarang, S. S., Utsuki, T., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207435200 · Cited by 551
Chen, L., Hambright, W. S., Na, R., & Ran, Q. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.680090 · Cited by 498 · cited 1×
“Induction of ferroptosis via conditional ablation of glutathione peroxidase 4 from neurons in adult mice induces a rapid paralysis phenotype coupled with muscle atrophy and death (Chen et al., 2015).”
Zecca, L., Stroppolo, A., Gatti, A., Tampellini, D., Toscani, M., Gallorini, M., Giaveri, G., Arosio, P., Santambrogio, P., Fariello, R. G., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403495101 · Cited by 495
Grx5 Is a Mitochondrial Glutaredoxin Required for the Activity of Iron/Sulfur Enzymes
Rodrı́guez-Manzaneque, M. T., Tamarit, J., Bellı́, G., Ros, J., & Herrero, E. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.01-10-0517 · Cited by 464
Zecca, L., Gallorini, M., Schünemann, V., Trautwein, A. X., Gerlach, M., Riederer, P., Vezzoni, P., & Tampellini, D. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00186.x · Cited by 401
Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury
Patel, B. N., Dunn, R. J., Jeong, S. Y., Zhu, Q., Julien, J.-P., & David, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06578.2002 · Cited by 379 · cited 1×
“stantia nigra iron and the development of parkinsonism (Ayton et al., 2013; Patel et al., 2002).”
Neuroprotective Function of DJ-1 in Parkinson’s Disease
Ariga, H., Takahashi-Niki, K., Kato, I., Maita, H., Niki, T., & Iguchi-Ariga, S. M. M. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/683920 · Cited by 373
Braak, H., & Del Tredici, K. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-179001 · Cited by 372
Deficiency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesis.
The Tübingen 2000 Screen Consortium, Wingert, R. A., Galloway, J. L., Barut, B., Foott, H., Fraenkel, P., Axe, J. L., Weber, G. J., Dooley, K., Davidson, A. J., et al. (2005) · Nature · doi:10.1038/nature03887 · Cited by 370
Locus coeruleus cellular and molecular pathology during the progression of Alzheimer’s disease
Kelly, S. C., He, B., Perez, S. E., Ginsberg, S. D., Mufson, E. J., & Counts, S. E. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0411-2 · Cited by 286 · cited 1×
“Neuronal loss from the locus coeruleus generally occurs later and is not quite as profound as degeneration in the substantia nigra pars compacta, and is also observed in Alzheimer's disease and Down syndrome (German et al., 1992; Kelly et al., 2017).”
Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease
Ayton, S., Lei, P., Duce, J. A., Wong, B. X. W., Sedjahtera, A., Adlard, P. A., Bush, A. I., & Finkelstein, D. I. (2013) · Annals of Neurology · doi:10.1002/ana.23817 · Cited by 264 · cited 8×
“1995), and 40 mg/kg actually increases substantia nigra copper by 19% (Ayton et al., 2013).”
InfluentialComplex I, iron, and ferritin in Parkinson's disease substantia nigra
Mann, V. M., Cooper, J. M., Daniel, S. E., Srai, K., Jenner, P., Marsden, C. D., & Schapira, A. H. V. (1994) · Annals of Neurology · doi:10.1002/ana.410360612 · Cited by 251 · cited 1×
“There is abundant evidence for impaired activity of mitochondrial complex I in PD post-mortem tissue, profoundly from SN, but also other brain regions including frontal cortex and the periphery (Bindoff et al., 1989; Mann et al., 1994; Mizuno et al., 1989; Parker et al., 1989, 2008; Schapira et al., 1990; Schapira et…”
Copper pathology in vulnerable brain regions in Parkinson's disease
Davies, K. M., Bohic, S., Carmona, A., Ortega, R., Cottam, V., Hare, D. J., Finberg, J. P. M., Reyes, S., Halliday, G. M., Mercer, J. F. B., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.034 · Cited by 244
Truban, D., Hou, X., Caulfield, T. R., Fiesel, F. C., & Springer, W. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160989 · Cited by 237
Iron in the basal ganglia in Parkinson's disease
Griffiths, P. D., Dobson, B. R., Jones, G. R., & Clarke, D. T. (1999) · Brain · doi:10.1093/brain/122.4.667 · Cited by 229
Mastroberardino, P. G., Hoffman, E. K., Horowitz, M. P., Betarbet, R., Taylor, G., Cheng, D., Na, H. M., Gutekunst, C.-A., Gearing, M., Trojanowski, J. Q., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.02.009 · Cited by 195
Reduced intravenous glutathione in the treatment of early parkinson's disease
Sechi, G., Deledda, M. G., Bua, G., Satta, W. M., Deiana, G. A., Pes, G. M., & Rosati, G. (1996) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(96)00103-0 · Cited by 173
Oestreicher, E., Sengstock, G. J., Riederer, P., Olanow, C. W., Dunn, A. J., & Arendash, G. W. (1994) · Brain Research · doi:10.1016/0006-8993(94)90833-8 · Cited by 156
Randomized, double‐blind, pilot evaluation of intravenous glutathione in Parkinson's disease
Hauser, R. A., Lyons, K. E., McClain, T., Carter, S., & Perlmutter, D. (2009) · Movement Disorders · doi:10.1002/mds.22401 · Cited by 143
UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2 G2019S carriers and in vivo
Mortiboys, H., Furmston, R., Bronstad, G., Aasly, J., Elliott, C., & Bandmann, O. (2015) · Neurology · doi:10.1212/wnl.0000000000001905 · Cited by 131 · cited 2×
“Indeed, complex IV activity is impaired in LRRK2 mutant PD patients (Mortiboys et al., 2015) and in mutated PINK1 and DJ-1 patient fibroblasts and animal models (Lopez-Fabuel et al.”
Olivieri, S., Conti, A., Iannaccone, S., Cannistraci, C. V., Campanella, A., Barbariga, M., Codazzi, F., Pelizzoni, I., Magnani, G., Pesca, M., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3768-11.2011 · Cited by 125
Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease
Hochstrasser, H., Bauer, P., Walter, U., Behnke, S., Spiegel, J., Csoti, I., Zeiler, B., Bornemann, A., Pahnke, J., Becker, G., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000144276.29988.c3 · Cited by 111
Compartmentalization of iron between mitochondria and the cytosol and its regulation
Mühlenhoff, U., Hoffmann, B., Richter, N., Rietzschel, N., Spantgar, F., Stehling, O., Uzarska, M. A., & Lill, R. (2015) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2015.05.003 · Cited by 95 · cited 1×
“As described above, Fe-S cluster assembly and trafficking are essential for coordination of iron metabolism via iron regulatory proteins (Muhlenhoff et al., 2015).”
Functional relevance of ceruloplasmin mutations in Parkinson's Disease
Hochstrasser, H., Tomiuk, J., Walter, U., Behnke, S., Spiegel, J., Krüger, R., Becker, G., Riess, O., & Berg, D. (2005) · The FASEB Journal · doi:10.1096/fj.04-3486fje · Cited by 87
The pathology roadmap in Parkinson disease
Surmeier, D. J., & Sulzer, D. (2013) · Prion · doi:10.4161/pri.23582 · Cited by 74
Masilamoni, G. J., Groover, O., & Smith, Y. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.025 · Cited by 37 · cited 1×
“Further evidence for mitochondrial impairment in the pathogenesis of PD comes from the selective sensitivity of the substantia nigra and locus coeruleus to mitochondrial toxins, including 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6hydroxydopamine, rotenone and paraquat (Giannoccaro et al., 2017; Masilamoni e…”
Glutathione-complexed [2Fe-2S] clusters function in Fe–S cluster storage and trafficking
Fidai, I., Wachnowsky, C., & Cowan, J. A. (2016) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-016-1387-2 · Cited by 29 · cited 1×
“Glutathione has recently been shown to directly coordinate with Fe-S clusters, potentially playing a role in trafficking Fe-S clusters (Fidai et al., 2016).”
Cited by
Nrf2 and Ferroptosis: A New Research Direction for Neurodegenerative Diseases
Song, X., & Long, D. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00267 · Cited by 577
Ferroptosis and Cancer: Mitochondria Meet the “Iron Maiden” Cell Death
Battaglia, A. M., Chirillo, R., Aversa, I., Sacco, A., Costanzo, F., & Biamonte, F. (2020) · Cells · doi:10.3390/cells9061505 · Cited by 561
Targeting Nrf2 to Suppress Ferroptosis and Mitochondrial Dysfunction in Neurodegeneration
Abdalkader, M., Lampinen, R., Kanninen, K. M., Malm, T. M., & Liddell, J. R. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00466 · Cited by 423
Self-citationThe application of Ferroptosis in diseases
Qiu, Y., Cao, Y., Cao, W., Jia, Y., & Lu, N. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104919 · Cited by 415
The Glutathione System in Parkinson’s Disease and Its Progression
Bjørklund, G., Peana, M., Maes, M., Dadar, M., & Severin, B. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.10.004 · Cited by 186
Metadata
- Authors
- Liddell, J. R., & White, A. R.
- Venue
- Neurochemistry International
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 117
- Pages
- 126-138
- ISSN
- 0197-0186 (ISSN-L)
- OpenAlex
- W2620911125
- Cited by
- 62
- References
- 42
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.